First Manhattan
MRNA icon

First Manhattan’s Moderna MRNA Stock Holding History

First Manhattan’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-475
Closed -$50.6K – 1068
2024
Q1 		$50.6K Sell
475
-251
-35% -$25.3K ﹤0.01% 890
2023
Q4 		$72.2K Buy
726
+1
+0.1% +$84 ﹤0.01% 803
2023
Q3 		$74.9K Hold
725
– – ﹤0.01% 805
2023
Q2 		$88.1K Sell
725
-10
-1% -$1.33K ﹤0.01% 793
2023
Q1 		$113K Sell
735
-123
-14% -$20.3K ﹤0.01% 783
2022
Q4 		$154K Sell
858
-2,347
-73% -$384K ﹤0.01% 747
2022
Q3 		$378K Hold
3,205
– – ﹤0.01% 561
2022
Q2 		$457K Sell
3,205
-4
-0.1% -$572 ﹤0.01% 557
2022
Q1 		$552K Sell
3,209
-236
-7% -$39.7K ﹤0.01% 562
2021
Q4 		$874K Buy
3,445
+2,770
+410% +$810K ﹤0.01% 455
2021
Q3 		$259K Hold
675
– – ﹤0.01% 681
2021
Q2 		$158K Hold
675
– – ﹤0.01% 777
2021
Q1 		$88K Sell
675
-225
-25% -$32.6K ﹤0.01% 847
2020
Q4 		$94K Sell
900
-250
-22% -$25.3K ﹤0.01% 800
2020
Q3 		$81K Buy
1,150
+850
+283% +$59.3K ﹤0.01% 806
2020
Q2 		$19K Buy
+300
New +$16.4K ﹤0.01% 1043

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

First Manhattan's MRNA Position: Q2 2024 in Review

First Manhattan sold out of Moderna (MRNA) in Q2 2024, closing a stake of 475 shares — an estimated $50.6K sold.

First Manhattan first reported a position in MRNA in Q2 2020 and held it in 16 quarters. The position peaked at $874K in Q4 2021. 954 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

  • First Manhattan reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
  • First Manhattan sold 475 Moderna shares in Q2 2024, an estimated $50.6K.
  • First Manhattan first reported a position in Moderna in Q2 2020 and held it in 16 quarters.
  • First Manhattan's Moderna position peaked at $874K in Q4 2021.
  • 954 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.